Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Colorectal Neoplasms

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 70 articles: HTML format

Single Articles

April 2026
1. SINICROPE FA, Sharma N, Mohiuddin M, Saberzadeh-Ardestani B, et al
   Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics Platform.
   Clin Cancer Res. 2026 Apr 17. doi: 10.1158/1078-0432.CCR-25-3711.
   PubMed     Abstract available
   
   
   
2. MORETTO R, Studiale V, Hyun SW, Vetere G, et al
   Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment.
   Clin Cancer Res. 2026 Apr 13. doi: 10.1158/1078-0432.CCR-25-4641.
   PubMed     Abstract available
   
   
   
3. AREF AT, Pathan M, Habib R, Hains PG, et al
   Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction using three independent cohorts.
   Clin Cancer Res. 2026 Apr 9. doi: 10.1158/1078-0432.CCR-25-3200.
   PubMed     Abstract available
   
   
   
4. SHEN Y, Wei M, He Y, Yang T, et al
   Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy.
   Clin Cancer Res. 2026;32:1293-1301.
   PubMed     Abstract available
   
   
   March 2026
5. CECCHINI M, Han SW, Lee S, Lee KW, et al
   The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.
   Clin Cancer Res. 2026 Mar 23. doi: 10.1158/1078-0432.CCR-25-3727.
   PubMed     Abstract available
   
   
   
6. AHN DH, Barzi A, Ridinger M, Samuelsz E, et al
   Correction: Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
   Clin Cancer Res. 2026;32:1180.
   PubMed    
   
   
   
7. HILLSON LVS, McMahon RK, Galbraith NJ, McCulloch AK, et al
   Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer.
   Clin Cancer Res. 2026;32:1145-1156.
   PubMed     Abstract available
   
   
   February 2026
8. BOIGE V, Bouche O, Mulot C, Evesque L, et al
   Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatment.
   Clin Cancer Res. 2026 Feb 11. doi: 10.1158/1078-0432.CCR-25-3555.
   PubMed     Abstract available
   
   
   
9. DEMING DA, Kraus SG, Brand J, Johnson KA, et al
   Tumor matrix proteoglycan accumulation and processing alters T cell effector function and the response to immunotherapy in patients with oligometastatic colorectal cancer.
   Clin Cancer Res. 2026 Feb 11. doi: 10.1158/1078-0432.CCR-25-2780.
   PubMed     Abstract available
   
   
   January 2026
10. SALEM ME, Puccini A, Mauer E, Andre T, et al
    Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.
    Clin Cancer Res. 2026;32:417-427.
    PubMed     Abstract available
    
    
    
11. PARSEGHIAN CM, Eluri M
    Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer.
    Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-4251.
    PubMed     Abstract available
    
    
    
12. KEYL J, Hosch R, Horst F, Keyl P, et al
    Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer.
    Clin Cancer Res. 2026 Jan 5. doi: 10.1158/1078-0432.CCR-25-3080.
    PubMed     Abstract available
    
    
    December 2025
13. MANCA P, Paoli M, Galardi F, Morano F, et al
    CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trial.
    Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2773.
    PubMed     Abstract available
    
    
    
14. CHRISTENSON ES, Ho WJ, Shu D, Durham JN, et al
    Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
    Clin Cancer Res. 2025;31:5317.
    PubMed    
    
    
    
15. BENT AH, Dasari A, Smith JJ
    Are We There Yet? The Telltale Trail of ctDNA in Rectal Cancer.
    Clin Cancer Res. 2025;31:5117-5119.
    PubMed     Abstract available
    
    
    
16. AKIYOSHI T, Shinozaki E, Maeda Y, Taguchi S, et al
    ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial.
    Clin Cancer Res. 2025;31:5188-5197.
    PubMed     Abstract available
    
    
    
17. XIA F, Chen Y, Zhou D, Wan J, et al
    Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study.
    Clin Cancer Res. 2025;31:4976-4984.
    PubMed     Abstract available
    
    
    November 2025
18. GERRITSE SL, Helden EJV, Arens AIJ, Boellaard R, et al
    Early [18F]FDG PET/CT response after a single dose of anti-EGFR therapy as a predictive biomarker for treatment benefit in patients with advanced colorectal cancer.
    Clin Cancer Res. 2025 Nov 10. doi: 10.1158/1078-0432.CCR-25-1768.
    PubMed     Abstract available
    
    
    
19. KASTINEN M, Harkonen J, Sirnio P, Elomaa H, et al
    Unraveling the effects and characteristics of proliferating tumor and cytotoxic T cells in colorectal cancer.
    Clin Cancer Res. 2025 Nov 7. doi: 10.1158/1078-0432.CCR-25-2026.
    PubMed     Abstract available
    
    
    October 2025
20. YEH C, Artz O, Zhang H, Karnoub ER, et al
    Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer.
    Clin Cancer Res. 2025 Oct 30. doi: 10.1158/1078-0432.CCR-25-2566.
    PubMed     Abstract available
    
    
    
21. BALLHAUSEN A, Swoboda S, Horst D, Fruehauf S, et al
    Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.
    Clin Cancer Res. 2025;31:4049-4058.
    PubMed     Abstract available
    
    
    September 2025
22. SMABERS LP, Wensink GE, Verissimo CS, Doorn M, et al
    Patient-derived organoids predict treatment response in metastatic colorectal cancer.
    Clin Cancer Res. 2025 Sep 22. doi: 10.1158/1078-0432.CCR-25-1564.
    PubMed     Abstract available
    
    
    August 2025
23. MICHAEL M, Wong R, Gill S, Strickland AH, et al
    The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.
    Clin Cancer Res. 2025;31:3452-3462.
    PubMed     Abstract available
    
    
    June 2025
24. MERIC-BERNSTAM F, Raghav KPS, Sweeney CJ, Swanton C, et al
    ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
    Clin Cancer Res. 2025 Jun 13:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-2763.
    PubMed     Abstract available
    
    
    
25. BERCZ A, Faden DL, Smith JJ, Romesser PB, et al
    Clocking Recurrence: Circulating Tumor HPV DNA Kinetics in Anal Cancer.
    Clin Cancer Res. 2025;31:2261-2263.
    PubMed     Abstract available
    
    
    
26. MORRIS VK, Xiao W, Lin K, Wong CW, et al
    Time Dependency for Human Papillomavirus Circulating Tumor DNA Detection after Chemoradiation as a Prognostic Biomarker for Localized Anal Cancer.
    Clin Cancer Res. 2025;31:2399-2405.
    PubMed     Abstract available
    
    
    May 2025
27. DREW DA, Downie JM, Chan AT
    "PIK"ing the right patients for adjuvant aspirin therapy for colorectal cancer.
    Clin Cancer Res. 2025 May 29. doi: 10.1158/1078-0432.CCR-25-0953.
    PubMed     Abstract available
    
    
    
28. XU N, Zhang DF, Shi XX, Yang KX, et al
    Identification and Targeting of POLQ-Associated Hereditary Colorectal Cancer.
    Clin Cancer Res. 2025 May 27. doi: 10.1158/1078-0432.CCR-25-0379.
    PubMed     Abstract available
    
    
    
29. CHRISTENSON ES, Ho WJ, Shu D, Durham JN, et al
    Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
    Clin Cancer Res. 2025 May 19. doi: 10.1158/1078-0432.CCR-25-0002.
    PubMed     Abstract available
    
    
    
30. MOMEN-ROKNABADI A, Karimzadeh M, Chen NC, Cavazos TB, et al
    Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence.
    Clin Cancer Res. 2025 May 14. doi: 10.1158/1078-0432.CCR-25-0449.
    PubMed     Abstract available
    
    
    
31. APPLEYARD JW, Williams CJM, Manca P, Pietrantonio F, et al
    Targeting the MAP kinase pathway in colorectal cancer: A journey in personalized medicine.
    Clin Cancer Res. 2025 May 1. doi: 10.1158/1078-0432.CCR-25-0107.
    PubMed     Abstract available
    
    
    
32. WANKHEDE D, Halama N, Kloor M, Edelmann D, et al
    Prognostic Value of CD8+ T Cells at the Invasive Margin Is Comparable to the Immune Score in Nonmetastatic Colorectal Cancer: A Prospective Multicentric Cohort Study.
    Clin Cancer Res. 2025;31:1711-1718.
    PubMed     Abstract available
    
    
    
33. MORRIS VK, Liu S, Lin K, Zhu H, et al
    Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.
    Clin Cancer Res. 2025;31:1657-1666.
    PubMed     Abstract available
    
    
    April 2025
34. ONG JC, Zhao JJ, Liu Y, Srivastava S, et al
    Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3780.
    PubMed     Abstract available
    
    
    
35. SIRKIA O, Karjalainen H, Elomaa H, Vayrynen SA, et al
    Multimarker assessment of B cell and plasma cell subsets and their prognostic role in the colorectal cancer microenvironment.
    Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-24-4083.
    PubMed     Abstract available
    
    
    
36. CHAUDHARY N, La Ferlita A, Choudhary BS, Jog E, et al
    Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas.
    Clin Cancer Res. 2025;31:1359-1373.
    PubMed     Abstract available
    
    
    March 2025
37. LI C, Noonan AM, Hays J, Roychowdhury S, et al
    Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase 1 Clinical Trial.
    Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3964.
    PubMed     Abstract available
    
    
    
38. GULLER U, Hayoz S, Horber D, Jochum W, et al
    Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial.
    Clin Cancer Res. 2025 Mar 11. doi: 10.1158/1078-0432.CCR-24-4048.
    PubMed     Abstract available
    
    
    
39. JAZIEH K, Tsai J, Solomon S, Zhu M, et al
    Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers.
    Clin Cancer Res. 2025;31:899-906.
    PubMed     Abstract available
    
    
    February 2025
40. HENRIKSEN TV, Demuth C, Frydendahl A, Nors J, et al
    Timing of circulating tumor DNA analysis aimed at guiding adjuvant treatment in colorectal cancer.
    Clin Cancer Res. 2025 Feb 20. doi: 10.1158/1078-0432.CCR-24-3200.
    PubMed     Abstract available
    
    
    
41. SABERZADEH-ARDESTANI B, Liu Z, Stein MI, Sherman WA, et al
    Spatially resolved, multi-region proteomics for prediction of immunotherapy outcome in deficient mismatch repair metastatic colorectal cancer.
    Clin Cancer Res. 2025 Feb 19. doi: 10.1158/1078-0432.CCR-24-0853.
    PubMed     Abstract available
    
    
    
42. SCHOENFELD JD, Azad NS, Gross J, Chen L, et al
    Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.
    Clin Cancer Res. 2025;31:667-677.
    PubMed     Abstract available
    
    
    
43. LIU C, Zou H, Ruan Y, Fang L, et al
    Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma.
    Clin Cancer Res. 2025;31:773-786.
    PubMed     Abstract available
    
    
    
44. CIOMBOR KK, Bae SW, Whisenant JG, Ayers GD, et al
    Results of the phase I/II study and preliminary B cell gene signature of combined inhibition of glutamine metabolism and EGFR in colorectal cancer.
    Clin Cancer Res. 2025 Feb 10. doi: 10.1158/1078-0432.CCR-24-3133.
    PubMed     Abstract available
    
    
    January 2025
45. XU C, Mannucci A, Esposito F, Oliveres H, et al
    An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-1934.
    PubMed     Abstract available
    
    
    
46. WEST EJ, Sadoun A, Bendjama K, Erbs P, et al
    A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2498.
    PubMed     Abstract available
    
    
    December 2024
47. GHIDINI M, Hahne JC, Senti C, Heide T, et al
    Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy.
    Clin Cancer Res. 2024 Dec 17. doi: 10.1158/1078-0432.CCR-24-0924.
    PubMed     Abstract available
    
    
    
48. PIETRANTONIO F, Morano F, Niger M, Ghelardi F, et al
    The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Phase 1b/2a Trial.
    Clin Cancer Res. 2024 Dec 2. doi: 10.1158/1078-0432.CCR-24-2611.
    PubMed     Abstract available
    
    
    November 2024
49. NAKAMURA Y, Kaneva K, Lo C, Neems D, et al
    A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-2396.
    PubMed     Abstract available
    
    
    October 2024
50. MACFARLAND SP, Becktell K, Schneider KW, Kuiper RP, et al
    Pediatric Cancer Screening in Hereditary Gastrointestinal Cancer Risk Syndromes: An Update from the AACR Childhood Cancer Predisposition Working Group.
    Clin Cancer Res. 2024;30:4566-4571.
    PubMed     Abstract available
    
    
    
51. ANDERSSON A, Escriva Conde M, Surova O, Vermeulen P, et al
    Spatial Transcriptome Mapping of the Desmoplastic Growth Pattern of Colorectal Liver Metastases by In Situ Sequencing Reveals a Biologically Relevant Zonation of the Desmoplastic Rim.
    Clin Cancer Res. 2024;30:4517-4529.
    PubMed     Abstract available
    
    
    September 2024
52. LEE HM, Saw AK, Morris VK, Napolitano S, et al
    Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-1166.
    PubMed     Abstract available
    
    
    August 2024
53. IIDA N, Imai M, Okamoto W, Kato T, et al
    Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 Aug 20:OF1-OF12. doi: 10.1158/1078-0432.CCR-24-1023.
    PubMed     Abstract available
    
    
    
54. DAS A, MacFarland SP, Meade J, Hansford JR, et al
    Clinical Updates and Surveillance Recommendations for DNA Replication Repair Deficiency Syndromes in Children and Young Adults.
    Clin Cancer Res. 2024;30:3378-3387.
    PubMed     Abstract available
    
    
    
55. NAKAMURA Y, Tsukada Y, Matsuhashi N, Murano T, et al
    Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay.
    Clin Cancer Res. 2024 Aug 7. doi: 10.1158/1078-0432.CCR-24-1651.
    PubMed     Abstract available
    
    
    
56. CHANG W, Zhang Z, Jia B, Ding K, et al
    A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study.
    Clin Cancer Res. 2024;30:3337-3348.
    PubMed     Abstract available
    
    
    June 2024
57. JOHANSEN AM, Forsythe SD, McGrath CT, Barker G, et al
    TGFbeta in pancreas and colorectal cancer: opportunities to overcome therapeutic resistance.
    Clin Cancer Res. 2024 Jun 25. doi: 10.1158/1078-0432.CCR-24-0468.
    PubMed     Abstract available
    
    
    
58. LENTZ RW, Friedrich TJ, Blatchford PJ, Jordan KR, et al
    A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer.
    Clin Cancer Res. 2024 Jun 13. doi: 10.1158/1078-0432.CCR-24-0090.
    PubMed     Abstract available
    
    
    
59. SLATER S, Bryant A, Aresu M, Begum R, et al
    Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study.
    Clin Cancer Res. 2024 Jun 12. doi: 10.1158/1078-0432.CCR-24-0226.
    PubMed     Abstract available
    
    
    May 2024
60. FUSCO MJ, Casak SJ, Mushti SL, Cheng J, et al
    FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281.
    PubMed     Abstract available
    
    
    
61. VOISIN A, Terret C, Schiffler C, Bidaux AS, et al
    Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.
    Clin Cancer Res. 2024;30:2111-2120.
    PubMed     Abstract available
    
    
    
62. LOREE JM, Titmuss E, Topham JT, Kennecke HF, et al
    Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.
    Clin Cancer Res. 2024 May 10. doi: 10.1158/1078-0432.CCR-24-0268.
    PubMed     Abstract available
    
    
    
63. PARIKH AR, Chee BH, Tsai J, Rich TA, et al
    Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Clin Cancer Res. 2024 May 2. doi: 10.1158/1078-0432.CCR-23-3660.
    PubMed     Abstract available
    
    
    
64. WU C, Pai RK, Kosiorek H, Banerjee I, et al
    Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
    Clin Cancer Res. 2024;30:1811-1821.
    PubMed     Abstract available
    
    
    
65. KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al
    Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Clin Cancer Res. 2024;30:1906-1915.
    PubMed     Abstract available
    
    
    April 2024
66. WILBUR HC, Le DT, Agarwal P
    Immunotherapy of MSI Cancer: Facts and Hopes.
    Clin Cancer Res. 2024;30:1438-1447.
    PubMed     Abstract available
    
    
    
67. MOUILLET-RICHARD S, Cazelles A, Sroussi M, Gallois C, et al
    Clinical challenges of consensus molecular subtype CMS4 colon cancer in the era of precision medicine.
    Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-3964.
    PubMed     Abstract available
    
    
    March 2024
68. HARROLD E, Keane F, Walch H, Chou JF, et al
    Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.
    Clin Cancer Res. 2024 Mar 19. doi: 10.1158/1078-0432.CCR-23-4005.
    PubMed     Abstract available
    
    
    
69. MALVIYA G, Lannagan TRM, Johnson E, Mackintosh A, et al
    Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging.
    Clin Cancer Res. 2024 Mar 17:OF1-OF12. doi: 10.1158/1078-0432.CCR-23-1063.
    PubMed     Abstract available
    
    
    
70. STEBBING J, Bullock AJ
    Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer.
    Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-24-0251.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum